Arizona launches Joltin’ Joe
NEW YORK — Arizona Beverages is saluting American icon and sports legend Joe DiMaggio with the launch of a lightly carbonated espresso drink called Joltin’ Joe.
Joltin’ Joe is a light, all-natural drink made with natural espresso coffee and features a clean, smooth taste followed by a subtle, bubbly effect, the company said. It contains 80-mg of caffeine and touts 50 calories per 8-oz. serving. Joltin’ Joe is packaged in 16-oz. aluminum cans that feature Joe DiMaggio, as well as historical photos and headlines from his 56-game hitting streak. Joltin’ Joe joins Arizona’s portfolio that includes Arnold Palmer half & half and Jack Nicklaus’ Golden Bear lines.
The beverage will be available in New York metro area in mid-September and will continue to roll out nationally throughout the year.
Report: Former HHS secretary Mike Leavitt to lead GOP hopeful’s health policy efforts
WASHINGTON — Former secretary for the Department of Health and Human Services Mike Leavitt will lead presidential hopeful Mitt Romney’s transition planning should Romney win the fall elections, according to a report published Wednesday by National Journal Daily.
Leavitt helped author the prescription coverage under Medicare Part D during his tenure at HHS.
According to the report, Leavitt, a former Utah governor, will also be in charge of implementing any health reforms under Romney. The report identified Tevi Troy, Leavitt‚ former deputy at HHS, and Thomas Barker, now a partner at Foley Hoag, who also worked for Leavitt at HHS as prominent members on Romney’s health advisory team, along with Scott Gottlieb, now with the American Enterprise Institute, who served as a senior adviser at the Centers for Medicare and Medicaid Services during the Bush years and later became a deputy commissioner at the Food and Drug Administration.
For the full report, click here.
Hospira buys Indian manufacturing, R&D center
LAKE FOREST, Ill. — Generic drug maker Hospira has acquired a manufacturing and research and development center from an Indian drug maker for $200 million, Hospira said Wednesday.
Hospira said it bought the Food and Drug Administration-approved active pharmaceutical ingredient factory and R&D facility in Aurangabad, India, from Orchid Chemicals and Pharmaceuticals, saying it would reduce Hospira’s costs, support its supplying of antibiotics and pave the way for future API development.
"Our decision to acquire Orchid’s world-class API facility demonstrates Hospira’s continued dedication to the antibiotics space, enchanting cost-competitiveness and ensuring continuity of supply," Hospira India managing director C. Bhaktavatsala Rao said. "This is a top-of-the-line API manufacturing facility that has been recognized by industry leaders for its high standards. We look forward to welcoming our new colleagues from Orchid and leveraging their expertise to continue to bring high-quality, lower-cost products to patients around the world."